Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | CASP2 | P42575 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | ICMT | O60725 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889317 | 1.00 | NAAA (0.61) | NAAACASP2DNM1FAAHSELP | |
| SCHEMBL889316 | 1.00 | NAAA (0.61) | NAAACASP2DNM1FAAHSELP | |
| SCHEMBL16638653 | 0.97 | NAAA (0.65) | NAAACASP2DNM1FAAHSELP | |
| SCHEMBL12792130 | 0.97 | NAAA (0.65) | NAAACASP2DNM1FAAHSELP | |
| SCHEMBL12792143 | 0.97 | NAAA (0.65) | NAAACASP2DNM1FAAHSELP | |
| SCHEMBL12791952 | 0.97 | NAAA (0.65) | NAAACASP2DNM1FAAHSELP | |
| SCHEMBL889270 | 0.95 | NAAA (0.63) | NAAACASP2DNM1FAAHSELP | |
| SCHEMBL889237 | 0.95 | NAAA (0.63) | NAAACASP2DNM1FAAHSELP | |
| SCHEMBL889233 | 0.95 | NAAA (0.63) | NAAACASP2DNM1FAAHSELP | |
| SCHEMBL24412748 | 0.94 | NAAA (0.69) | NAAACASP2DNM1FAAHSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | NAAA 789/4885CASP2 2840/4885DNM1 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.